Literature DB >> 31644388

Opioid prescribing patterns and overdose deaths in Texas.

Tiffany Champagne-Langabeer1, Renita Madu2, Sharmila Giri1, Angela L Stotts3, James R Langabeer1,4.   

Abstract

BACKGROUND: Opioid use disorder has recently been declared a public health emergency, yet it is unknown whether opioid prescribing patterns have changed over time. Our objective is to examine opioid prescribing behavior and overdose fatalities in one large state prior to state-mandated usage of a prescription drug monitoring program (PDMP).
Methods: We relied on de-identified longitudinal data from state and national databases for opioid prescriptions and overdose deaths in Texas between 2013 and 2017. Descriptive statistics and trend analyses were used to assess proportional differences and changes over time.
Results: Prescriptions for opioids represented over 45% of the total controlled medications dispensed across the entire period. This equates to roughly 17.7 million opioid prescriptions dispensed per year, or 63.7 opioid prescriptions per 100 persons, slightly less than the reported national average. Hydrocodone was the most widely prescribed opioid (32.9%), followed by tramadol (26.9%) and codeine (21.5%). The overall controlled substance prescribing rate appears to be decreasing in the latest year, and the composition of opioids has shifted. We found a reduction in schedule II medications (such as hydrocodone and fentanyl) and increase in schedule IV medications such as tramadol. At the same time, total overdose fatalities increased 42% during this time, and population-adjusted rates increased 34% to 5.87 deaths per 100,000 persons. Conclusions: While prescribing rates have decreased in Texas, overdose deaths from both legal and illicit opioids are rising, suggesting that changing physician prescribing behavior alone may not be sufficient to curb the epidemic. Policies and community interventions should be considered to address increases in both prescription and illicit opioid deaths.

Entities:  

Keywords:  Opioids; overdose deaths; prescribing patterns; prescription drug monitoring program

Year:  2019        PMID: 31644388     DOI: 10.1080/08897077.2019.1675114

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  6 in total

1.  Advances in prescription drug monitoring program research: a literature synthesis (June 2018 to December 2019).

Authors:  Chris Delcher; Nathan Pauly; Patience Moyo
Journal:  Curr Opin Psychiatry       Date:  2020-07       Impact factor: 4.787

2.  Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications.

Authors:  Callie G Downs; Tyler J Varisco; Shweta S Bapat; Chan Shen; J Douglas Thornton
Journal:  Res Social Adm Pharm       Date:  2020-06-03

3.  Feasibility and outcomes from an integrated bridge treatment program for opioid use disorder.

Authors:  James R Langabeer; Tiffany Champagne-Langabeer; Andrea J Yatsco; Meredith M O'Neal; Marylou Cardenas-Turanzas; Samuel Prater; Samuel Luber; Angela Stotts; Tom Fadial; Gina Khraish; Henry Wang; Bentley J Bobrow; Kimberly A Chambers
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-03-31

4.  Prevalence of Mental Health Disorders among Individuals Enrolled in an Emergency Response Program for Treatment of Opioid Use Disorder.

Authors:  Christine Bakos-Block; James R Langabeer; Andrea Yatsco; Marylou Cardenas-Turanzas; Tiffany Champagne-Langabeer
Journal:  Subst Abuse       Date:  2020-12-21

5.  National patterns of cessation of prescription opioids among Medicare beneficiaries, 2013-2018.

Authors:  Jordan Westra; Mukaila Raji; Yong-Fang Kuo
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

6.  Actual situation and prescribing patterns of opioids by pain physicians in South Korea.

Authors:  Min Jung Kim; Ji Yeon Kim; Yun Hee Lim; Sung Jun Hong; Jae Hun Jeong; Hey Ran Choi; Sun Kyung Park; Jung Eun Kim; Min Ki Lee; Jae Hun Kim
Journal:  Korean J Pain       Date:  2022-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.